Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 12

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 12
---
 trial using INKmune to treat patients
with metastatic castrate resistant prostate cancer is an open label trial. Biomarker data from the patients will be visible as patients
are treated. The Company will report data from each cohort as it becomes available. Because of the modified Bayesian design, the Company
estimates the trial will be completely enrolled 1H25 with top-line data available 6 months later. Topline data is divided into immunologic
and tumor response variables. The most important immunologic response variable is related to memory like NK cell persistence. This is
how long are the number of mlNK cells in patients blood compared to baseline. There are 3 important variables to tumor response: i) blood
PSA changes; ii) change in PMSA scan and iii) change in circulating tumor DNA (ctDNA). Ideally, the levels of all three variables decrease
with treatment. We do not expect this 6-month trial to provide survival data.

Recent Developments

Registered Direct Offering

On September 12, 2024, the Company entered into
securities purchase agreements with investors and certain directors, officers, and employees of the Company for the purchase and sale
by the Company of 2,341,260 shares of the Company’s common stock and warrants to purchase an additional 2,341,260 shares
of the Company’s common stock exercisable six months from the issuance date in a registered direct offering in exchange for gross
proceeds of $13.0 million, before deducting placement agent fees and expenses (the “September 2024 Offering”). Directors and
officers that participated in the offering paid a combined offering price of $6.50 per share and warrant, and other investors paid
$5.50 per share and warrant. The exercise price of the warrants is $6.40, and the warrants are exercisable beginning on March 16,
2025 and will terminate on March 16, 2030 unless accelerated pursuant to the terms of the warrants.

<div align='center'>S-4</div>

ATM Offering

We and BTIG, LLC, as sales agent (“BTIG”),
entered into an At-the-Market-Sales Agreement, dated March 10, 2021 (the “Sales Agreement”) as amended, on August 16, 2023
(“Amendment No. 1 to the Sales Agreement”). On August 9, 2024, we entered into an Amended and Restated At-The-M